"A comparitive study of efficacy of two different drug combination in reducing adverse events due to the process of insertion of endotracheal tube into the larynx in hypertensive patient "

"A comparitive study of efficacy of propofol with fentanyl and etomidate with fentanyl in attenuation of hemodynamic response and sequelae of laryngoscopy and endotracheal intubation in hypertensive patients"

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037562

Enrollment

Registered

2021-10-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension Health Condition 2: I10- Essential (primary) hypertension Health Condition 3: I10- Essential (primary) hypertension

Interventions

Intervention1: Group P: Inj propofol 2mg/kg IV stat inj fentanyl 2mcg/kg IV stat Over 30 seconds Intervention2: Group E : Inj Etomidate 0.3mg/kg IV stat Inj Fentanyl 2mcg/kg IV stat Over 30 seconds

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA physical status II 2.Patients with normal ( modified Mallampatti class I or II )

Exclusion criteria

Exclusion criteria: 1.refusal by patients for the procedure 2.ASA physical status 3 and 4 3.uncontrolled hypertension ( >160/90mmhg) 4.patient with the history of hypersensitivity to inj propofol and inj etomidate 5.Anticipated difficult airway 6.patient with cardiovascular diseases other than hypertension, epilepsy, renal, hepatic disease 7.Brochial asthma and COPD 8.presence of known primary or secondary adrenal insufficiency or on steroid medication

Design outcomes

Primary

Measure	Time frame
to study the hemodynamic response during laryngoscopy and endotracheal intubation using inj propofol with inj fentanyl and inj etomidate with inj fentanyl in hypertensive patientsTimepoint: basal parameters , pre-induction,after-induction, 1min,2min,3min,5min after intubation	—

Secondary

Measure	Time frame
To study the adverse effects like pain on injection, myoclonus, nausea, vomiting, ST elevationTimepoint: During and after intubation	—

Countries

India

Contacts

Public ContactDr Srinivasalu D

Vijaynagar institute of medical sciences, ballari

gautamgauti94@gmail.com8095441788

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026